Table 1. Baseline characteristics.
| Characteristic | Overall (n=312) | Non cancer (n=259) | Cancer patients (n=53) | p-value |
|---|---|---|---|---|
| Age (yr) | 68.1±6.2 (51.00–82.00) | 67.6±6.1 (51.00–82.00) | 70.3±5.9 (58.00–81.00) | 0.005 |
| Total PSA (ng/mL) | 13.27±2.71 (9.95–20.01) | 13.36±2.67 (9.95–20.01) | 12.82±2.89 (10.07–19.58) | 0.182 |
| Prostate volume (mL) | 64.0±28.5 (12.00–179.00) | 67.3±28.0 (20.00–179.00) | 48.0±25.7 (12.00–117.00) | <0.001 |
| Repeated biopsy (%) | 52 (16.7) | 45 (17.4) | 7 (13.2) | 0.458 |
| %fPSA | 0.21±0.11 (0.05–1.08) | 0.22±0.11 (0.06–1.08) | 0.17±0.73 (0.05–0.42) | <0.001 |
| %p2PSA | 1.05±0.53 (0.12–4.66) | 0.94±0.37 (0.12–3.01) | 1.55±0.83 (0.29–4.66) | <0.001 |
| PHI | 37.53±19.64 (4.16–179.28) | 33.96±13.78 (4.16–108.33) | 54.95±31.51 (13.04–179.28) | <0.001 |
Values are presented as mean±standard deviation (range) or number (%).
PSA, prostate specific antigen; %fPSA, %free-to-total PSA; %p2PSA, percentage of [-2]pro-prostate-specific antigen; PHI, Prostate Health Index.